Comparative Pharmacology
Head-to-head clinical analysis: AUGMENTIN 200 versus NALLPEN IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AUGMENTIN 200 versus NALLPEN IN PLASTIC CONTAINER.
AUGMENTIN '200' vs NALLPEN IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), while clavulanate irreversibly inhibits beta-lactamases, preventing degradation of amoxicillin.
Nallpen is a penicillinase-resistant penicillin that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), specifically active against beta-lactamase-producing Staphylococcus aureus.
One 200 mg amoxicillin/28.5 mg clavulanate chewable tablet every 8 hours for mild to moderate infections; for severe infections, one 400 mg/57 mg tablet every 12 hours or one 200 mg/28.5 mg tablet every 8 hours.
Nafcillin 1-2 g IV every 4 hours for moderate to severe infections; for MSSA bacteremia or endocarditis, 2 g IV every 4 hours.
None Documented
None Documented
Amoxicillin: ~1 hour in healthy adults, prolonged to 7-20 hours in renal impairment (CrCl <10 mL/min). Clavulanate: ~1 hour, similarly prolonged in renal impairment. The combination's half-life supports twice-daily dosing for most infections.
0.9-1.2 hours; prolonged in renal impairment (up to 7-10 hours in anuria); requires dose adjustment for CrCl <30 mL/min
Amoxicillin: ~50-70% excreted unchanged in urine via glomerular filtration and tubular secretion, with the remainder hepatically metabolized and excreted in bile and feces. Clavulanate: ~30-50% excreted unchanged in urine, the rest metabolized and eliminated in bile and feces.
Primarily renal (60-80% unchanged drug via glomerular filtration and tubular secretion); biliary/fecal: minor (<5%)
Category C
Category C
Penicillin Antibiotic
Penicillin Antibiotic